BioAge Labs, Inc.

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Our technology platform and differentiated human datasets help us identify promising targets based on insights into molecular changes that drive aging. In January 2025, we announced our lead program, BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor. BGE-102 has a distinct mechanism and binding site from other NLRP3 inhibitors in development, with issued patents covering both its composition and claims for its unique binding site. In December 2025, we announced that BGE-102 was well-tolerated in Single Ascending Dose (SAD) and initial Multiple Ascending Dose (MAD) cohorts, with a pharmacokinetic profile supporting once-daily oral dosing, strong target engagement, and high brain penetration. We intend to advance BGE-102 in two therapeutic areas: cardiometabolic disease and ophthalmology. Our first therapeutic area for BGE-102 is cardiometabolic disease, focusing on atherosclerotic cardiovascular disease (ASCVD) risk reduction. Chronic systemic inflammation, measured by high-sensitivity C-reactive protein (hsCRP), is an independent risk factor for cardiovascular events not adequately addressed by current lipid-lowering and antihypertensive therapies. In January 2026, we announced additional positive interim Phase 1 data, demonstrating potential for hsCRP reduction in participants with elevated cardiovascular risk. In obese participants with elevated hsCRP, BGE-102 showed an 86% median reduction in hsCRP at Day 14, with 93% of participants achieving hsCRP levels below 2 mg/L. We anticipate full Phase 1 SAD / MAD clinical trial results in the first half of 2026. Our second therapeutic area for BGE-102 is ophthalmology, with diabetic macular edema (DME) as our first proof-of-concept indication.